Phase II prospective multicenter study for stage I/II Follicular Lymphoma treated with
involved-field radiotherapy (IFRT) at doses of 24 Gy) with or without Ofatumumab for 8 weekly
doses on molecular basis. Patients with positive basal Bcl-2 will be followed every 3 months
and with Bcl-2 detection every 6 months for 3 years. Patient with negative basal Bcl-2 will
be followed every 3 months without further Bcl-2 detection.
Ofatumumab treatment will be administered to:
1. Patients with positive basal PCR for Bcl-2-IgH rearrangement in BM and/or PB, resulting
still positive after IFRT;
2. Patients with positive basal PCR for Bcl-2-IgH in